PVLA
Palvella Therapeutics, Inc.Healthcare·Biotechnology
$118.46
$1.4B market cap
Revenue
$0.0M
Free Cash Flow
$-15.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of o
2-Year Price History
$113.99+738.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -14.9 | -14.9 | -15.8 | -10.9 | -10.9 | -0.0 | 261.9 | 0.6 | 13.1 | -27.8% | -7.3x | -- |
| Act | 2025-Q4 | 0.0 | -11.0 | -11.3 | -12.7 | -4.9 | -4.9 | -0.0 | 58.0 | 0.6 | 11.3 | -464.9% | -6.3x | -- |
Valuation & Metrics
Market Stats
Price$118.46
Market Cap$1.4B
Enterprise Value$1.1B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-28.5M
Free Cash Flow$-15.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-246.3%
WC Change % Rev0.0%
Interest Coverage-86.1x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.2M
Days to Cover10.7
Change (vs Prior)+9.7%
Need at least 2 settlement dates for chart
Employees
Headcount14
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
100.3%(+90.9% YoY)
167 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
18.7%(+18.0% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.0% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $144M | $47.87 | +$32.5M | +$54.7M | -9.2% | $3.69B |
| First Light Asset Management, LLC | $122M | $87.02 | +$33.9M | +$122M | -10.4% | $1.12B |
| BVF INC/IL | $120M | $38.38 | +$10.2M | +$33.0M | -0.5% | $3.14B |
| Frazier Life Sciences Management, L.P. | $110M | $33.47 | +$19.9M | +$24.0M | +2.1% | $3.89B |
| BlackRock, Inc.Passive | $85.6M | $53.15 | +$15.9M | +$71.8M | -0.2% | $5.69T |
| JENNISON ASSOCIATES LLC | $79.9M | $105.56 | +$31.6M | +$79.9M | +2.7% | $145.31B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $59.5M | $124.65 | +$59.5M | +$59.5M | — | $4.04T |
| STATE STREET CORPPassive | $57.2M | $86.76 | +$4.8M | +$55.7M | -0.2% | $2.89T |
| FEDERATED HERMES, INC. | $54.0M | $74.80 | +$8.1M | +$54.0M | -1.1% | $61.33B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $50.2M | $124.07 | +$49.7M | +$50.2M | -0.2% | $864.93B |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $46.6M | $124.65 | +$46.6M | +$46.6M | -0.5% | $9.65B |
| Woodline Partners LP | $39.6M | $28.58 | +$2.1M | +$15.4M | -0.1% | $26.43B |
| Siren, L.L.C. | $32.1M | $118.83 | +$22.7M | +$32.1M | +6.1% | $3.61B |
| EVENTIDE ASSET MANAGEMENT, LLC | $29.0M | $115.93 | +$16.4M | +$29.0M | -1.6% | $5.96B |
| ALLIANCEBERNSTEIN L.P. | $27.5M | $104.67 | −$772K | +$27.5M | -0.3% | $307.70B |
| FMR LLC | $26.9M | $84.65 | −$2.0M | +$26.9M | -0.0% | $1.89T |
| MPM BioImpact LLC | $25.7M | $91.02 | +$82K | +$25.7M | -1.8% | $1.29B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $25.6M | $40.97 | +$3.3M | +$13.9M | +2.3% | $1.61T |
| PRIMECAP MANAGEMENT CO/CA/ | $24.3M | $124.65 | +$24.3M | +$24.3M | +0.4% | $127.01B |
| GOLDMAN SACHS GROUP INC | $24.2M | $70.46 | +$11.9M | +$21.8M | -0.2% | $760.93B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.61%
avg per quarter
Holders (ex-self)
-1.69%
excl. this stock
Buyers (this Q)
-1.37%
129 buyers · $0.76B in
Sellers (this Q)
+0.36%
32 sellers · $0.02B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.6%
how holders react when this stock falls
On quiet Qs
-4.4%
−10% to +10% baseline
On rallies (+10%+)
+2.1%
how they react when this stock rises
Holders' portfolio flow this Q
-0.6%
outflows — trims may be forced
Sellers' portfolio flow this Q
+10.4%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.8%
Holder mid (any stock)
-4.4%
Holder rally (any stock)
-6.5%
Biggest decreases this quarter
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLCexited−$40.8MPERCEPTIVE ADVISORS LLCexited−$27.9MArtia Global Partners LPexited−$6.2MSUPERSTRING CAPITAL MANAGEMENT LPexited−$2.7MArtisan Partners Limited Partnership−$2.2Mα-0.4FMR LLC−$2.0Mα-0.0Verition Fund Management LLCexited−$1.2MCatalio Capital Management, LPexited−$1.1MMARSHALL WACE, LLPexited−$993KCinctive Capital Management LPexited−$911K
New buyers this quarter
Top-5 holders · 35.5%
SUVRETTA CAPITAL MANAGEMENT, LLC--
First Light Asset Management, LLC--
BVF INC/IL--
Frazier Life Sciences Management, L.P.--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
SUVRETTA CAPITAL MANAGEMENT, LLC1.2MFirst Light Asset Management, LLC981KBVF INC/IL961KFrazier Life Sciences Management, L.P.882KJENNISON ASSOCIATES LLC641KFEDERATED HERMES, INC.433KPRICE T ROWE ASSOCIATES INC /MD/403KFRONTIER CAPITAL MANAGEMENT CO LLC374KSUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC—Woodline Partners LP318K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (5 analysts)$229.009330.0%
Last Year (29 analysts)$163.973840.0%
Current Price$118.46
Analyst Ratings
1
9
Strong Buy: 1Buy: 9Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$850K
3 txns · 2 insiders · 6,845 sh
Sells ($, 12mo)
$3.08M
7 txns · 1 insider · 30,114 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $110.56 | $476K | $0 |
| 2026-04-15 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $127.24 | $547K | $0 |
| 2026-03-30 | BUY | JENKINS GEORGE M | director | 445 | $112.30 | $50K | $21.07M |
| 2026-03-18 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $117.99 | $508K | $0 |
| 2026-02-27 | BUY | HERON ELAINE J | director | 2,400 | $125.00 | $300K | $5.98M |
| 2026-02-27 | BUY | JENKINS GEORGE M | director | 4,000 | $125.00 | $500K | $23.40M |
| 2026-02-18 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $79.40 | $342K | $0 |
| 2026-01-21 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $97.63 | $420K | $0 |
| 2025-12-17 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $96.47 | $415K | $0 |
| 2025-11-19 | SELL | Goin Kathleen | officer: Chief Operating Officer | 4,302 | $86.23 | $371K | $0 |
Order Flow (FINRA, ~3w lag)
17.3%retail+1.5pp
19.0%dark-5.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Palvella Therapeutics: High-Interest Royalty Debt and Impending Dilution Tsunami
Overall Risk
8/10
Fraud
3/10
Dilution
9/10
Insolvency
6/10
Earnings Overstated
2/10
Hidden Liabilities
7/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
4/10